Hypersensitivity to dipyrone in aspirin-exacerbated respiratory disease patients is associated with urticaria

Imagem de Miniatura
Arquivos
art_AGONDI_Hypersensitivity_to_dipyrone_in_aspirinexacerbated_respiratory_disease_patients_2020.PDF.PDF (410.29 KB)
Citações na Scopus
0
Tipo de produção
article
Data de publicação
2020
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
W B SAUNDERS CO LTD
Autores
Citação
RESPIRATORY MEDICINE, v.170, article ID 106041, 5p, 2020
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Objective: To phenotype patients with aspirin-exacerbated respiratory disease (AERD) according to the presence of atopy, urticaria and level of peripheral eosinophils. Methods: This study included adult asthmatic patients with AERD followed up at a tertiary hospital. They were classified according to atopy and/or urticaria, assessing clinical and laboratorial differences among the groups in order to identify possible aggravating factors of the disease. Results: We included 73 patients, 78.1% being female with a mean age of 54.0 years. Severe asthma was observed in 68.5% and respiratory exacerbation with dipyrone in 67.1% of these patients. They had median total serum IgE of 191.6 IU/mL, mean peripheral eosinophils of 718.5 cells/mm(3), and 50.7% were atopic. Urticaria was observed in 32.9% of them, and exacerbations were more often triggered by dipyrone (p = .016). Atopic patients were younger than nonatopic patients (p = .023), and had, on average, higher total serum IgE levels (p = .022). We observed a good correlation between asthma severity and peripheral eosinophils count (r(2) = 026; p = .021). Conclusions: In this study, severe asthma was highly prevalent in AERD patients. Likewise, urticaria was quite prevalent and its presence was associated with dipyrone induced hypersensitivity reaction. Atopy was found in half of the patients, with no association with asthma severity. Patients with higher levels of peripheral eosinophils had more severe asthma. Dypirone hypersensitivity may be a marker for concomitant respiratory and cutaneous hypersensitivity reactions.
Palavras-chave
Aspirin-exacerbated respiratory disease (AERD), Eosinophils, Atopy, Urticaria, Dipyrone
URI
https://observatorio.fm.usp.br/handle/OPI/37625
Referências
  1. [Anonymous], GLOB STRAT ASTHM MAN
  2. Aun MV, 2014, J ALLER CL IMM-PRACT, V2, P414, DOI [10.1016/j.jaip.2014.03.014, 10.1016/j.jaip.2014.08.015]
  3. Blanca-Lopez N, 2015, J INVEST ALLERG CLIN, V25, P259
  4. Blanca-Lopez N, 2019, J ASTHMA ALLERGY, V12, P217, DOI 10.2147/JAA.S164806
  5. Blanca-Lopez N, 2016, INT ARCH ALLERGY IMM, V169, P223, DOI 10.1159/000444798
  6. Bochenek G, 2015, RESP MED, V109, P588, DOI 10.1016/j.rmed.2015.02.015
  7. Bochenek G, 2014, J ALLERGY CLIN IMMUN, V133, P98, DOI 10.1016/j.jaci.2013.07.004
  8. Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x
  9. Casciano J, 2016, BMC PULM MED, V16, DOI 10.1186/s12890-016-0271-8
  10. Comhair SAA, 2018, RESP RES, V19, DOI 10.1186/s12931-018-0909-6
  11. DelGaudio JM, 2019, INT FORUM ALLERGY RH, V9, P1017, DOI 10.1002/alr.22367
  12. Dona I, 2011, CLIN EXP ALLERGY, V41, P86, DOI 10.1111/j.1365-2222.2010.03651.x
  13. Dona I, 2020, ALLERGY, V75, P561, DOI 10.1111/all.14032
  14. Dona I, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-34668-1
  15. Giavina-Bianchi P, 2019, ANN ALLERG ASTHMA IM, V122, P447, DOI 10.1016/j.anai.2019.02.007
  16. Heinzerling L, 2005, ALLERGY, V60, P1287, DOI 10.1111/j.1398-9995.2005.00895.x
  17. Hellings PW, 2017, ALLERGY, V72, P1657, DOI 10.1111/all.13200
  18. Hinz B, 2007, FASEB J, V21, P2343, DOI 10.1096/fj.06-8061com
  19. Hopkins C, 2019, NEW ENGL J MED, V381, P55, DOI 10.1056/NEJMcp1800215
  20. Jasiecka A, 2014, POL J VET SCI, V17, P207, DOI 10.2478/pjvs-2014-0030
  21. Kowalski ML, 2013, ALLERGY, V68, P1219, DOI 10.1111/all.12260
  22. Kowalski ML, 2019, CURR OPIN PULM MED, V25, P64, DOI 10.1097/MCP.0000000000000530
  23. Kowalski ML, 2019, ALLERGY, V74, P28, DOI 10.1111/all.13599
  24. Laidlaw TM, 2019, ALLERGY ASTHMA PROC, V40, P4, DOI 10.2500/aap.2019.40.4188
  25. Lee HY, 2017, ALLERGY, V72, P616, DOI 10.1111/all.13075
  26. Pellegrino R, 2005, EUR RESPIR J, V26, P948, DOI 10.1183/09031936.05.00035205
  27. Pierre SC, 2007, BRIT J PHARMACOL, V151, P494, DOI 10.1038/sj.bjp.0707239
  28. Price DB, 2015, LANCET RESP MED, V3, P849, DOI 10.1016/S2213-2600(15)00367-7
  29. Rajan JP, 2015, J ALLERGY CLIN IMMUN, V135, P676, DOI 10.1016/j.jaci.2014.08.020
  30. Stevenson DD, 2016, IMMUNOL ALLERGY CLIN, V36, P643, DOI 10.1016/j.iac.2016.06.002
  31. Szczeklik A, 2003, J ALLERGY CLIN IMMUN, V111, P913, DOI 10.1067/mai.2003.1487
  32. Wilson KF, 2014, INT FORUM ALLERGY RH, V4, P93, DOI 10.1002/alr.21258
  33. Zuberbier T, 2018, ALLERGY, V73, P1393, DOI 10.1111/all.13397

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - HC/InCor
Artigos e Materiais de Revistas Científicas - LIM/19
Artigos e Materiais de Revistas Científicas - LIM/60
Artigos e Materiais de Revistas Científicas - ODS/03